YDES · YD Bio Ltd
$2.98
+0.47 (+18.73%)
At close · Aug 14
Market Cap
$211.08M
Shares
70.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.98
Open$2.76
Day$2.42–3.24
52W close$1.90–23.11
Avg vol 30d218K
Short int16K · 0.0% float · 1.0d
Short vol41%
DataAug 2025–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−59%
below
Price vs 50-day avg
+21%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
−63%
trailing
YTD return
−76%
this year
Relative strength
−77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+50% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of float · ▼ -35.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
12 holders — near 1-yr high, broad support
Squeeze score
30
low risk · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
Gross margin
28%
contracting
EPS growth
−500%
Y/Y
Free cash flow
$-8.0M
Balance sheet
$6.0M
net cash
Quant / Vol
risk profile
Volatility
195%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
11.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−59%
Bearish
Price vs 50-day avg
+21%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+50% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of float · ▼ -35.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
12 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $3 · 5%
Range high $23
vs 200-day avg -59%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
YDES
this stock
YD Bio Ltd
|
$211.08M | -75.6% | +16.9% | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
12
- % held
- 0.4%
- Net QoQ
- +123.1K sh
- Top holder
- Garrett Wealth Advisory G…
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| YDES | +29.9% | +21.6% | -63.4% | +37.3% | -75.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +29.5% | +17.2% | -77.1% | +33.4% | -89.4% |
Key facts
CIK
2011674
CUSIP
G98301107
13F (30d)
12 filings
12 filers
Visit website
Investor relations